Sacubitril-Valsartan

Overview

4.6 out of 5 (16 Reviews)

Credits

1.00

Pharmacology Credits

1.00

Post Assessment Questions

7

Start Date

1 Sep 2023

Last Review Date

29 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Sacubitril-valsartan is the first agent approved in a new class of drugs called angiotensin receptor neprilysin inhibitor (ARNI). The medication is FDA-approved to treat patients with chronic heart failure with reduced ejection fraction (HFrEF) in NYHA class II, III, or IV. Sacubitril-valsartan is used instead of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) and in conjunction with other standard heart-failure treatments (beta-blocker or aldosterone antagonist). Patients must be able to tolerate ACEi or ARB before starting sacubitril or valsartan. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, toxicity, and monitoring of sacubitril or valsartan so clinicians can appropriately treat patients with heart failure and related cardiovascular conditions.


Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Identify appropriate candidates for sacubitril-valsartan therapy based on current guidelines and patient characteristics.

  • Differentiate between sacubitril-valsartan and other heart failure therapies regarding the mechanism of action, efficacy, and safety profiles.

  • Assess patient response to sacubitril-valsartan therapy by monitoring symptoms, biomarkers, and adverse events.

  • Collaborate with interdisciplinary healthcare team members to ensure coordinated care and monitoring for patients receiving sacubitril-valsartan.

  • Outline the indications of Sacubitril-Valsartan

Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Nurse Practitioners: StatPearls designates this activity for 1.00 ANCC contact hour(s), which includes 1.00 hour(s) of pharmacology. NPs should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Mfon A. on 4/19/2021

Sarah A. on 11/17/2021

Mary Y. on 4/21/2022

Edward H. on 7/26/2022

Nicole G. on 9/1/2022

Michael D. on 9/24/2022

thanks

Valentine C. on 9/27/2022

Richard N. on 10/27/2022

jubril o. on 1/22/2023

Dr.NIRMALA M. on 1/28/2023

STUART B. on 2/5/2023

Katherine U. on 2/18/2023

Melissa B. on 2/28/2023

Persida D. on 8/31/2023

Kathleen on 9/4/2023

Valentine C. on 9/20/2023

Unlimited Nurse Practitioner CE

Stay up to date on the latest medical knowledge with 6675 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7930 hours of CE.

Single Activity

Take this single activity

$49 1 activity

6 Month Unlimited Nurse Practitioner CE

Access to all the Unlimited Nurse Practitioner CE activities in all specialties.

$379 per half year per user

1 Year Unlimited Nurse Practitioner CE

Access to all the Unlimited Nurse Practitioner CE activities in all specialties.

$579 per 1 year per user